IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NERE APPLICATION OF: Elizabeth King, et al.

PLICATION NO.: 09/425,622

FILING DATE: October 22, 1999 Examiner: J. Spear

: Group Art Unit: 1615 hereby certify that this correspondent

s being deposited with the United Sales Postal Service as First Class Mail in an

TITLE: Controlled-Release Pharmaceutical Formulations pe addressed to: Assistant Commissioner

for Patents, Washington, D.C. 20231 on

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Offce a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTOFB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is thought to be due for this submission since (1) the foreign language article has already been submitted; and (2) the instant submission is simply the translation thereof. If the Honorable Commissioner disagrees, however, the Commissioner is authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: OctoBER 16,

Jan⁄des T. Jones (

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc. Patent Department, Box 519 Eastern Point Road Groton, CT 06340 (860) 441-4903